Dr. Frits van Rhee is a Professor of Medicine and Director of Developmental and Translational Medicine at the UAMS Myeloma Institute. Dr. van Rhee earned his medical degree from Erasmus University, Rotterdam, Netherlands and his PhD at the Imperial College of Science, Medicine and Technology, University of London. He trained in internal medicine and hematology in the UK, and in bone marrow transplantation at John Radcliffe University Hospital in Oxford and the Royal Postgraduate Medical School in London. Dr. van Rhee holds the Charles and Clydene Scharlau Chair for Hematological Malignancies.
Dr. van Rhee is a renowned myeloma physician who treats and follows more than 800 patients with multiple myeloma, MGUS and smoldering myeloma, as well as other hematologic malignancies. He is a leading innovator in immunotherapy research and clinical applications, especially for patients with high-risk disease. Dr. van Rhee has been the principal investigator of NIH grants studying natural killer (NK) cell activity via cellular and vaccine-based approaches in myeloma.